BRAF Biomarkers News and reporting on BRAF biomarkers. Jun 23, 2022 MD Anderson Study Explains Differing BRAF/MEK Treatment Responses in Male, Female Melanoma Patients Premium Jun 23, 2022 Novartis Nets Tumor-Agnostic Approval for Tafinlar-Mekinist Combo Jun 14, 2022 Day One Bio's Tovorafenib Market Prospects Look Promising Based on Pediatric Glioma Trial Data Premium Jun 6, 2022 With ASCO Data, Novartis' Tafinlar-Mekinist Heads Toward FDA for BRAF-Mutant Pediatric Brain Cancer Premium Apr 26, 2022 Black Diamond Therapeutics to Discontinue ErbB Inhibitor Program, Lay Off 30 Percent of Workforce Apr 11, 2022 As NCI-MATCH Winds Down, Cancer Research Community Takes Stock of Lessons Learned Premium Mar 17, 2022 NCI-MATCH Umbrella Trial Adds Arm for LAG-3 Expressing, Mismatch Repair Deficient Cancers Mar 10, 2022 Erasca, Eli Lilly Partner to Study ERAS-007, Erbitux in BRAF V600E-Mutant Colorectal Cancer Feb 11, 2022 Seattle Cancer Care Alliance Aims to Improve Molecular Profiling Access for Thyroid Cancer Patients Premium Feb 4, 2022 CHOP Researchers Find Gene Fusions are Harbingers of Aggressive Disease in Pediatric Thyroid Cancer Premium Jan 4, 2022 MSK, Amgen Explore Lumakras Combination Regimens to Overcome KRAS Inhibitor Resistance Premium Dec 9, 2021 SABCS Clinicogenomic Study Sheds Light on HER2-Targeted Therapy Resistance Nov 24, 2021 Opdivo-Yervoy Before Tafinlar-Mekinist Provides Optimal Benefit to BRAF-Mutant Melanoma Patients Premium Nov 22, 2021 Day One Biopharmaceuticals Begins Phase II Trial in RAF-Altered Solid Tumors Nov 1, 2021 Kinnate Biopharma, Guardant Health Partner for Study of BRAF Mutations in Solid Tumors Sep 22, 2021 Erasca Begins Phase Ib/II Master Protocol Trial of ERAS-007 in Gastrointestinal Cancers Sep 16, 2021 Cedars-Sinai Researchers Hunt for Rx Options for RAF-Mutated Pancreatic Cancer in Real-World Data Premium Sep 13, 2021 Instil Bio to Begin Phase II Trial of TIL Therapy for Advanced Melanoma Sep 8, 2021 Pfizer, Erasca Partner to Study Three-Drug Combo in BRAF V600E-Mutated Metastatic Colon Cancer Aug 20, 2021 Long-term NCI Follow-up of TIL Therapy for Melanoma Sheds Light on Potential Frontline Benefit Load More Breaking News FDA Approves Taiho Oncology's Lytgobi for FGFR2-Rearranged Bile Duct Cancer Gladstone Institute Joins With Parker Institute on New Center to Study CRISPR-Based Cell Therapies Meliora Therapeutics Raises $11M in Seed Financing In Brief This Week:Â Verismo Therapeutics, Fore Biotherapeutics, Merck, Caris Life Sciences Tumor-Only Sequencing Found to Overestimate Mutational Burden in Non-European Patients Atara Biotherapeutics to Net $30M From Pierre Fabre for European Tab-Cel Approval
